CA2660286A1 - Organ-specific proteins and methods of their use - Google Patents
Organ-specific proteins and methods of their use Download PDFInfo
- Publication number
- CA2660286A1 CA2660286A1 CA002660286A CA2660286A CA2660286A1 CA 2660286 A1 CA2660286 A1 CA 2660286A1 CA 002660286 A CA002660286 A CA 002660286A CA 2660286 A CA2660286 A CA 2660286A CA 2660286 A1 CA2660286 A1 CA 2660286A1
- Authority
- CA
- Canada
- Prior art keywords
- organ
- specific proteins
- specific
- disease
- detection reagents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 880
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 851
- 210000000056 organ Anatomy 0.000 title claims abstract description 694
- 238000000034 method Methods 0.000 title claims abstract description 213
- 238000001514 detection method Methods 0.000 claims abstract description 234
- 210000004369 blood Anatomy 0.000 claims abstract description 227
- 239000008280 blood Substances 0.000 claims abstract description 227
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 213
- 201000010099 disease Diseases 0.000 claims description 217
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 217
- 239000000523 sample Substances 0.000 claims description 186
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 109
- 238000004949 mass spectrometry Methods 0.000 claims description 90
- 210000001519 tissue Anatomy 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 64
- 210000004556 brain Anatomy 0.000 claims description 36
- 238000003556 assay Methods 0.000 claims description 31
- 210000002307 prostate Anatomy 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 23
- 230000004044 response Effects 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 18
- 210000004291 uterus Anatomy 0.000 claims description 18
- 108091023037 Aptamer Proteins 0.000 claims description 17
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 16
- 206010060862 Prostate cancer Diseases 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 210000001072 colon Anatomy 0.000 claims description 13
- 210000002216 heart Anatomy 0.000 claims description 13
- 210000004072 lung Anatomy 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 210000003734 kidney Anatomy 0.000 claims description 11
- 238000012544 monitoring process Methods 0.000 claims description 11
- 210000004100 adrenal gland Anatomy 0.000 claims description 10
- 210000005075 mammary gland Anatomy 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 10
- 210000000813 small intestine Anatomy 0.000 claims description 10
- 210000000952 spleen Anatomy 0.000 claims description 10
- 210000002784 stomach Anatomy 0.000 claims description 10
- 210000001550 testis Anatomy 0.000 claims description 9
- 210000001541 thymus gland Anatomy 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 210000004727 amygdala Anatomy 0.000 claims description 7
- 210000001185 bone marrow Anatomy 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 7
- 210000001525 retina Anatomy 0.000 claims description 7
- 210000003079 salivary gland Anatomy 0.000 claims description 7
- 210000000278 spinal cord Anatomy 0.000 claims description 7
- 210000001685 thyroid gland Anatomy 0.000 claims description 7
- 206010062767 Hypophysitis Diseases 0.000 claims description 6
- 210000003635 pituitary gland Anatomy 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 208000017497 prostate disease Diseases 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 108091008103 RNA aptamers Proteins 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000019399 Colonic disease Diseases 0.000 claims description 2
- 108091008102 DNA aptamers Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000029162 bladder disease Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000026533 urinary bladder disease Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 201000006306 Cor pulmonale Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 208000025584 Pericardial disease Diseases 0.000 claims 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 34
- 238000003491 array Methods 0.000 abstract description 24
- 239000013060 biological fluid Substances 0.000 abstract description 8
- 235000018102 proteins Nutrition 0.000 description 678
- 239000002157 polynucleotide Substances 0.000 description 154
- 102000040430 polynucleotide Human genes 0.000 description 154
- 108091033319 polynucleotide Proteins 0.000 description 154
- 125000003275 alpha amino acid group Chemical group 0.000 description 149
- 150000007523 nucleic acids Chemical class 0.000 description 119
- 102000039446 nucleic acids Human genes 0.000 description 97
- 108020004707 nucleic acids Proteins 0.000 description 97
- 102000004196 processed proteins & peptides Human genes 0.000 description 84
- 229920001184 polypeptide Polymers 0.000 description 72
- 230000003321 amplification Effects 0.000 description 70
- 238000003199 nucleic acid amplification method Methods 0.000 description 70
- 230000014509 gene expression Effects 0.000 description 67
- 239000013615 primer Substances 0.000 description 55
- 210000002966 serum Anatomy 0.000 description 53
- 108091034117 Oligonucleotide Proteins 0.000 description 47
- 108020004635 Complementary DNA Proteins 0.000 description 35
- 102000053602 DNA Human genes 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 34
- 238000010804 cDNA synthesis Methods 0.000 description 34
- 239000002299 complementary DNA Substances 0.000 description 34
- 229920002477 rna polymer Polymers 0.000 description 34
- 238000009396 hybridization Methods 0.000 description 32
- 230000036541 health Effects 0.000 description 27
- 239000000758 substrate Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 25
- 101000692709 Drosophila melanogaster Pre-intermoult gene 1 protein Proteins 0.000 description 22
- 230000000295 complement effect Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 19
- 230000000875 corresponding effect Effects 0.000 description 19
- 230000004048 modification Effects 0.000 description 19
- 238000012986 modification Methods 0.000 description 18
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
- -1 nanoparticies Proteins 0.000 description 17
- 238000004422 calculation algorithm Methods 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 102100034343 Integrase Human genes 0.000 description 15
- 239000012491 analyte Substances 0.000 description 15
- 210000004999 sex organ Anatomy 0.000 description 15
- 102000004506 Blood Proteins Human genes 0.000 description 14
- 108010017384 Blood Proteins Proteins 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000002853 nucleic acid probe Substances 0.000 description 13
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 12
- 238000002493 microarray Methods 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 108091093037 Peptide nucleic acid Proteins 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 210000001124 body fluid Anatomy 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 210000003932 urinary bladder Anatomy 0.000 description 10
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 9
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 239000002356 single layer Substances 0.000 description 8
- 210000003437 trachea Anatomy 0.000 description 8
- 102100035024 Carboxypeptidase B Human genes 0.000 description 7
- 102100030072 Doublesex- and mab-3-related transcription factor 3 Human genes 0.000 description 7
- 101000797917 Homo sapiens 1,5-anhydro-D-fructose reductase Proteins 0.000 description 7
- 101000946524 Homo sapiens Carboxypeptidase B Proteins 0.000 description 7
- 101000864825 Homo sapiens Doublesex- and mab-3-related transcription factor 3 Proteins 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 7
- 239000010408 film Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000007834 ligase chain reaction Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 102000018247 Lymphocyte-specific proteins Human genes 0.000 description 6
- 108050007388 Lymphocyte-specific proteins Proteins 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000003679 cervix uteri Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 210000003016 hypothalamus Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 210000000064 prostate epithelial cell Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 238000004885 tandem mass spectrometry Methods 0.000 description 6
- 210000001103 thalamus Anatomy 0.000 description 6
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 210000001159 caudate nucleus Anatomy 0.000 description 5
- 210000000877 corpus callosum Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000000132 electrospray ionisation Methods 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 238000003498 protein array Methods 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 101710203526 Integrase Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 102100037611 Lysophospholipase Human genes 0.000 description 3
- 108010058864 Phospholipases A2 Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 238000001360 collision-induced dissociation Methods 0.000 description 3
- 238000000205 computational method Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000005040 ion trap Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229910000510 noble metal Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000026447 protein localization Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000003196 serial analysis of gene expression Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 229910052581 Si3N4 Inorganic materials 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000069 breast epithelial cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002349 difference gel electrophoresis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002977 intracellular fluid Anatomy 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 239000002070 nanowire Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000003499 nucleic acid array Methods 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000001819 pancreatic juice Anatomy 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000005240 physical vapour deposition Methods 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000000623 plasma-assisted chemical vapour deposition Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002294 pubertal effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000012508 resin bead Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- ULIKDJVNUXNQHS-UHFFFAOYSA-N 2-Propene-1-thiol Chemical compound SCC=C ULIKDJVNUXNQHS-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- 102100040006 Annexin A1 Human genes 0.000 description 1
- 108090000663 Annexin A1 Proteins 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 229910001020 Au alloy Inorganic materials 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000010207 Bayesian analysis Methods 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000700114 Chinchillidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 102100038385 Coiled-coil domain-containing protein R3HCC1L Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000251948 Dolophilodes major Species 0.000 description 1
- 102100027094 Echinoderm microtubule-associated protein-like 1 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 1
- 101710136552 Fatty acid-binding protein, heart Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000743767 Homo sapiens Coiled-coil domain-containing protein R3HCC1L Proteins 0.000 description 1
- 101001057941 Homo sapiens Echinoderm microtubule-associated protein-like 1 Proteins 0.000 description 1
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 1
- 101000666131 Homo sapiens Protein-glutamine gamma-glutamyltransferase 4 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 1
- 101000653787 Mus musculus Protein S100-A11 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100027370 Parathymosin Human genes 0.000 description 1
- 101710178700 Parathymosin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001665 Poly-4-vinylphenol Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100038103 Protein-glutamine gamma-glutamyltransferase 4 Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000269622 Salamandridae Species 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 101710159478 Thioredoxin-like protein Proteins 0.000 description 1
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001801 Z-test Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003686 blood clotting factor concentrate Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 238000000533 capillary isoelectric focusing Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000005566 electron beam evaporation Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003353 gold alloy Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000000148 multi-dimensional chromatography Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000004884 risky behavior Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002094 self assembled monolayer Substances 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 229910052990 silicon hydride Inorganic materials 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000006918 subunit interaction Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83698606P | 2006-08-09 | 2006-08-09 | |
| US60/836,986 | 2006-08-09 | ||
| PCT/US2007/017868 WO2008021290A2 (en) | 2006-08-09 | 2007-08-09 | Organ-specific proteins and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2660286A1 true CA2660286A1 (en) | 2008-02-21 |
Family
ID=39082660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002660286A Abandoned CA2660286A1 (en) | 2006-08-09 | 2007-08-09 | Organ-specific proteins and methods of their use |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8586006B2 (enExample) |
| EP (2) | EP2057465A4 (enExample) |
| JP (1) | JP5244103B2 (enExample) |
| AU (1) | AU2007284651B2 (enExample) |
| CA (1) | CA2660286A1 (enExample) |
| WO (1) | WO2008021290A2 (enExample) |
Families Citing this family (365)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| AU2005316169B2 (en) | 2004-12-13 | 2011-11-17 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| JP5376948B2 (ja) * | 2005-09-13 | 2013-12-25 | ナショナル リサーチ カウンシル オブ カナダ | 腫瘍細胞活性を調節する方法及び組成物 |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| US20120128661A1 (en) * | 2006-06-23 | 2012-05-24 | Alethia Biotherapeutics Inc. | Polynucleotide and polypeptide sequences involved in cancer |
| EP2502628B1 (en) * | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| JP5244103B2 (ja) * | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
| ES2625259T3 (es) | 2006-08-29 | 2017-07-19 | Oxford Biotherapeutics Ltd | Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón |
| WO2008057795A2 (en) * | 2006-10-27 | 2008-05-15 | Temple University - Of The Commonwealth System Of Higher Education | Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera |
| US20100143949A1 (en) * | 2006-10-31 | 2010-06-10 | George Mason Intellectual Properties, Inc. | Biomarkers for colorectal cancer |
| CA2915168C (en) | 2007-01-30 | 2017-05-23 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| US20090062144A1 (en) * | 2007-04-03 | 2009-03-05 | Nancy Lan Guo | Gene signature for prognosis and diagnosis of lung cancer |
| WO2008128161A2 (en) * | 2007-04-13 | 2008-10-23 | University Of Florida Research Foundation Inc. | Identification of cardiac specific myosin light chain kinase |
| AU2008259792B2 (en) * | 2007-06-03 | 2013-08-22 | Oncotx, Inc. | Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets |
| FR2919062B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal. |
| FR2919063B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal. |
| FR2919064B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal |
| FR2919065B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal |
| FR2919060B1 (fr) | 2007-07-19 | 2012-11-30 | Biomerieux Sa | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal. |
| CA2693098C (fr) | 2007-07-19 | 2019-06-18 | Yasemin Ataman-Onal | Procede de dosage de la proteine de liaison hepatique aux acides gras, de l'antigene carcino-embryonnaire, et de l'antigene carbohydrate 19-9 pour le diagnostic in vitro du cancercolorectal |
| FR2919061B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal. |
| CA2694112A1 (en) * | 2007-07-20 | 2009-01-29 | The University Of Utah Research Foundation | Identification and quantification of biomarkers for evaluating the risk of preterm birth |
| DE102007036678B4 (de) * | 2007-08-03 | 2015-05-21 | Sirs-Lab Gmbh | Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion |
| EP3241846B1 (en) * | 2007-10-04 | 2022-02-23 | ZymoGenetics, Inc. | B7 family member zb7h6 and related compositions and methods |
| AU2008313274A1 (en) * | 2007-10-19 | 2009-04-23 | Rappaport Family Institute For Research In The Medical Sciences | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
| US9808506B2 (en) | 2007-10-19 | 2017-11-07 | Rappaport Family Institute For Research In The Medical Sciences | Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof |
| US20110160072A1 (en) * | 2007-10-23 | 2011-06-30 | Clinical Genomics Pty. Ltd. | Method of diagnosing neoplasms |
| US9404932B2 (en) * | 2007-11-05 | 2016-08-02 | Nordic Bioscience A/S | Pathology biomarker assay |
| US9549971B2 (en) * | 2008-01-14 | 2017-01-24 | Genentech, Inc. | Methods for inhibiting angiogenesis using EGFL8 antagonists |
| MX2010009894A (es) | 2008-03-14 | 2011-02-22 | Transgene Sa | Anticuerpo contra csf-1r. |
| US8470977B2 (en) * | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| JP2011522224A (ja) * | 2008-04-21 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | 膵ベータ細胞質量生物マーカー |
| US8173369B2 (en) * | 2008-05-15 | 2012-05-08 | The Regents Of The University Of California | Peripheral gene expression biomarkers for autism |
| JP5428527B2 (ja) | 2008-06-03 | 2014-02-26 | 住友化学株式会社 | 化学物質が有する発生毒性の予測方法 |
| FR2933773B1 (fr) * | 2008-07-10 | 2013-02-15 | Biomerieux Sa | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal |
| WO2010012306A1 (en) * | 2008-07-31 | 2010-02-04 | Queen Mary And Westfield College, University Of London | Healthy kidney biomarkers |
| EP2161031A1 (en) * | 2008-09-05 | 2010-03-10 | SuppreMol GmbH | Fc gamma receptor for the treatment of B cell mediated multiple sclerosis |
| WO2010060186A1 (en) | 2008-11-03 | 2010-06-03 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| BRPI1007483B1 (pt) | 2009-01-28 | 2021-11-30 | Bio Preventive Medicine Corporation | Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia |
| DK2623517T3 (en) * | 2009-01-28 | 2015-11-23 | Ind Tech Res Inst | Urine and serum biomarkers associated with diabetic nephropathy |
| EP2524928A1 (en) * | 2011-05-18 | 2012-11-21 | Atlas Antibodies AB | RBM3 in bladder cancer |
| EP2221066A1 (en) | 2009-02-18 | 2010-08-25 | Sanofi-Aventis | Use of VgII3 activity modulator for the modulation of adipogenesis |
| WO2010099477A2 (en) | 2009-02-27 | 2010-09-02 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
| BRPI1009232B1 (pt) | 2009-03-05 | 2022-05-03 | E.R. Squibb & Sons, Llc. | Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1 |
| GB0904382D0 (en) * | 2009-03-13 | 2009-04-29 | Univ Dundee | Treatment of cell proliferation and differentiation disorders |
| US8404242B2 (en) | 2009-03-16 | 2013-03-26 | Atyr Pharma, Inc. | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| US20100310576A1 (en) | 2009-03-31 | 2010-12-09 | Adams Ryan A | COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES |
| US8399663B2 (en) | 2009-04-03 | 2013-03-19 | Astellas Pharma Inc. | Salt of 1,3,5-triazine-2,4,6-triamine derivative |
| WO2010115286A1 (en) * | 2009-04-09 | 2010-10-14 | Centre For Addiction And Mental Health | Dopamine d2 receptor-disc1 interaction, compositions and methods for modulating same |
| EP2438170A4 (en) * | 2009-06-05 | 2012-12-26 | Univ North Carolina | SOGA POLYNUCLEOTIDES AND POLYPEPTIDES AND ITS USES |
| CA2767616A1 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| JP6028960B2 (ja) * | 2009-07-14 | 2016-11-24 | 国立研究開発法人産業技術総合研究所 | 肝疾患病態指標糖鎖マーカー |
| CA2768042C (en) * | 2009-07-24 | 2017-11-21 | Universite De Montreal | Bret-based biosensors and methods for monitoring raf dimerization |
| US9410965B2 (en) * | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| EP2483690A1 (de) * | 2009-09-29 | 2012-08-08 | Protagen AG | Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung |
| JP5695383B2 (ja) | 2009-10-05 | 2015-04-01 | 花王株式会社 | 毛髪形状感受性遺伝子 |
| JP5695384B2 (ja) | 2009-10-05 | 2015-04-01 | 花王株式会社 | 毛髪形状感受性遺伝子 |
| JP5695385B2 (ja) | 2009-10-05 | 2015-04-01 | 花王株式会社 | 毛髪形状感受性遺伝子 |
| US10288617B2 (en) | 2009-10-26 | 2019-05-14 | Externautics Spa | Ovary tumor markers and methods of use thereof |
| US8921058B2 (en) | 2009-10-26 | 2014-12-30 | Externautics Spa | Prostate tumor markers and methods of use thereof |
| US9588121B2 (en) | 2009-11-06 | 2017-03-07 | Go Therapeutics, Inc. | Method for early detection of cancer |
| WO2011063523A1 (en) | 2009-11-24 | 2011-06-03 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| AU2010324686B2 (en) | 2009-11-30 | 2016-05-19 | Genentech, Inc. | Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 ) |
| WO2011067624A1 (en) * | 2009-12-01 | 2011-06-09 | Universita' Degli Studi Di Modena E Reggio Emilia | Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer |
| US9127268B2 (en) | 2009-12-11 | 2015-09-08 | Atyr Pharma, Inc. | Aminoacyl tRNA synthetases for modulating inflammation |
| US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
| WO2011100472A1 (en) * | 2010-02-10 | 2011-08-18 | The Regents Of The University Of California | Salivary transcriptomic and proteomic biomarkers for breast cancer detection |
| SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| US10627412B2 (en) * | 2010-03-17 | 2020-04-21 | Kagoshima University | Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same |
| US9067084B2 (en) * | 2010-03-31 | 2015-06-30 | Agency For Science, Technology And Research | Amphiphilic linear peptide/peptoid and hydrogel comprising the same |
| JP6066900B2 (ja) | 2010-04-26 | 2017-01-25 | エータイアー ファーマ， インコーポレイテッド | システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
| ES2638311T3 (es) | 2010-04-27 | 2017-10-19 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, diagnósticas y de anticuerpos relacionadas con fragmentos de proteína de treonil ARNt sintetasas |
| JP6008837B2 (ja) | 2010-04-28 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| US8986680B2 (en) | 2010-04-29 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
| WO2011139907A2 (en) | 2010-04-29 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
| AU2011248227B2 (en) | 2010-05-03 | 2016-12-01 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| US8759298B2 (en) | 2010-05-03 | 2014-06-24 | Scott & White Healthcare | Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration |
| CA2797799C (en) | 2010-05-03 | 2020-12-08 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases |
| US8961961B2 (en) | 2010-05-03 | 2015-02-24 | a Tyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases |
| JP6008841B2 (ja) | 2010-05-03 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| US9089588B2 (en) * | 2010-05-03 | 2015-07-28 | Curna, Inc. | Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) |
| JP6008843B2 (ja) | 2010-05-04 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | グルタミル−プロリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| EP2566499B1 (en) | 2010-05-04 | 2017-01-25 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
| EP2568996B1 (en) | 2010-05-14 | 2017-10-04 | aTyr Pharma, Inc. | Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
| AU2011256366C1 (en) | 2010-05-17 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
| GB201008541D0 (en) * | 2010-05-21 | 2010-07-07 | Univ Geneve | Diagnostic methods |
| CN103096913B (zh) | 2010-05-27 | 2017-07-18 | Atyr 医药公司 | 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| ES2619569T3 (es) | 2010-05-31 | 2017-06-26 | University Hospital Of Basel | Método de ensayo de infección o inflamación de las vías respiratorias inferiores |
| CA2800281C (en) | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| JP5855094B2 (ja) | 2010-06-03 | 2016-02-09 | アイデックス ラボラトリーズ インコーポレイテッドＩＤＥＸＸ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． | 腎疾患のためのマーカー |
| AU2015230872B2 (en) * | 2010-06-03 | 2017-05-11 | Idexx Laboratories, Inc. | Markers for renal disease |
| CA2804416C (en) | 2010-07-12 | 2020-04-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
| CA2804278C (en) | 2010-07-12 | 2021-07-13 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases |
| US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| KR20130102534A (ko) | 2010-07-12 | 2013-09-17 | 에이티와이알 파마, 인코포레이티드 | 히스티딜trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견 |
| JP6603009B2 (ja) | 2010-08-13 | 2019-11-06 | アリゾナ ボード オブ リージェンツ ア ボディー コーポレート アクティング オン ビハーフ オブ アリゾナ ステイト ユニバーシティ | 乳がんの検出を補助する方法、並びに乳がん検出用のポリペプチドプローブセット |
| WO2012023622A1 (ja) * | 2010-08-16 | 2012-02-23 | 国立大学法人九州大学 | 腫瘍の検査用試薬及び腫瘍の予防用医薬組成物 |
| JP5964304B2 (ja) | 2010-08-25 | 2016-08-03 | エータイアー ファーマ， インコーポレイテッド | チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| EP2612345B1 (en) * | 2010-09-02 | 2020-04-08 | University of the Sciences in Philadelphia | System and method for ionization of molecules for mass spectrometry and ion mobility spectrometry |
| WO2012035066A1 (en) * | 2010-09-14 | 2012-03-22 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschften E.V. | Hot1 and uses thereof |
| EP2619324B1 (en) * | 2010-09-23 | 2018-04-25 | Qiagen GmbH | Method for detecting and/or quantifying human dna |
| EP2624857B1 (en) | 2010-10-06 | 2017-08-02 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl trna synthetases |
| FR2968560A1 (fr) * | 2010-12-13 | 2012-06-15 | Oreal | Utilisation de l'ide comme biomarqueur d'un etat du cuir chevelu |
| MX2013008252A (es) * | 2011-01-18 | 2014-04-14 | Everist Genomics Inc | Firma de pronostico para la recurrencia de cancer colorrectal. |
| FR2970968A1 (fr) * | 2011-02-01 | 2012-08-03 | Isp Investments Inc | Nouveaux peptides intervenant dans la voie de signalisation scf c-kit et compositions les comprenant |
| US9364414B2 (en) | 2011-02-01 | 2016-06-14 | Isp Investments Inc. | Method to protect skin from ultraviolet radiation using novel peptides involved in the improvement of microparasol organization in keratinocytes |
| US9157125B2 (en) | 2011-02-02 | 2015-10-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | GRIN2A mutations and use thereof for the diagnosis of melanoma |
| WO2012118988A1 (en) * | 2011-03-01 | 2012-09-07 | The Scripps Research Institute | Direct reprogramming of human fibroblasts to functional neurons under defined conditions |
| JP2012197258A (ja) * | 2011-03-23 | 2012-10-18 | Tohoku Univ | 個別化治療診断のためのマーカータンパク質絶対量の定量方法 |
| WO2012135008A1 (en) * | 2011-03-26 | 2012-10-04 | Oregon Health And Science University | Gene expression predictors of cancer prognosis |
| JP5800180B2 (ja) * | 2011-03-28 | 2015-10-28 | 国立大学法人 長崎大学 | 日焼けの原因遺伝子 |
| DK3173427T3 (da) | 2011-03-31 | 2019-08-05 | Adc Therapeutics Sa | Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf |
| SI2694106T1 (en) | 2011-04-01 | 2018-04-30 | Immunogen, Inc. | Methods for increasing the effectiveness of treatment with FOLR1 receptor cancer |
| AU2012239880B2 (en) | 2011-04-08 | 2017-06-15 | Tufts Medical Center, Inc. | Pepducin design and use |
| US9409987B2 (en) * | 2011-04-15 | 2016-08-09 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| CA2833257A1 (en) * | 2011-04-15 | 2012-10-18 | Children's Medical Center Corporation | Diagnostic markers and therapeutic targets of kawasaki disease |
| WO2012149481A1 (en) * | 2011-04-27 | 2012-11-01 | The Board Of Regents On The University Of Texas System | Novel peptide inhibitors of serotonin 5-ht2c receptor:pten interaction |
| EP2707712A2 (en) * | 2011-05-13 | 2014-03-19 | King's College London | Methods and compositions relating to platelet sensitivity |
| US9290555B2 (en) | 2011-05-27 | 2016-03-22 | University Of Washington Through Its Center For Commercialization | Reagents and methods for treating dental disease |
| EP2715367A2 (en) * | 2011-06-03 | 2014-04-09 | University of South Alabama | Methods and compositions for detecting endometrial or ovarian cancer |
| EP2738250B1 (en) * | 2011-07-26 | 2017-11-15 | National Institute of Advanced Industrial Science And Technology | Anti-beta1,6-N-acetylglucosaminyltransferase 5B antibody for detecting epithelial ovarian cancer and method for diagnosing epithelial ovarian cancer |
| US9714419B2 (en) | 2011-08-09 | 2017-07-25 | Atyr Pharma, Inc. | PEGylated tyrosyl-tRNA synthetase polypeptides |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| CN102337285A (zh) * | 2011-10-25 | 2012-02-01 | 上海交通大学医学院附属仁济医院 | 一种含HIhh的逆转录病毒载体和病毒颗粒及其应用 |
| CA2856205A1 (en) * | 2011-11-15 | 2013-05-23 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
| US9816084B2 (en) | 2011-12-06 | 2017-11-14 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetases |
| WO2013086228A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Pegylated aspartyl-trna synthetase polypeptides |
| CN104093734A (zh) * | 2011-12-21 | 2014-10-08 | 明尼苏达大学董事会 | 阳离子肽和这类肽抑制外毒素产生的用途 |
| CA2858613A1 (en) | 2011-12-29 | 2013-08-08 | Atyr Pharma, Inc. | Aspartyl-trna synthetase-fc conjugates |
| HRP20190946T1 (hr) | 2012-01-09 | 2019-07-26 | Adc Therapeutics Sa | Sredstva za liječenje trostruko negativnog raka dojke |
| WO2013108561A1 (ja) | 2012-01-16 | 2013-07-25 | ライオン株式会社 | メタボリックシンドローム罹患リスク判定用マーカーペプチドおよびその用途 |
| DE102012100781B4 (de) | 2012-01-31 | 2013-08-14 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Forensisches Verfahren |
| JP6170077B2 (ja) | 2012-02-16 | 2017-07-26 | エータイアー ファーマ， インコーポレイテッド | 自己免疫および炎症疾患を処置するためのヒスチジルｔＲＮＡ合成酵素 |
| US9345755B2 (en) * | 2012-02-20 | 2016-05-24 | University Of Virginia Patent Foundation | Composition and methods for treating melanoma |
| CA2862739A1 (en) | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| CA2865575C (en) | 2012-02-27 | 2024-01-16 | Cellular Research, Inc. | Compositions and kits for molecular counting |
| WO2013135836A1 (en) * | 2012-03-14 | 2013-09-19 | Centre Hospitalier Universitaire Pontchaillou | Itih5 as a diagnostic marker of uterine development and functional defects |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| WO2013155567A1 (en) * | 2012-04-20 | 2013-10-24 | Mat Malta Advanced Technologies Limited | Sex determination genes |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| JP6441215B2 (ja) | 2012-05-16 | 2018-12-19 | エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． | 肺組織像を細分類するためのｓｒｍ／ｍｒｍ分析 |
| US9526760B2 (en) * | 2012-05-21 | 2016-12-27 | The Regents Of The University Of Colorado, A Body Corporate | LEDGF peptides and formulations thereof for treatment of degenerative disorders |
| WO2013184482A1 (en) * | 2012-06-04 | 2013-12-12 | Yale University | Method of treating and preventing ocular angiogenesis |
| WO2013184912A2 (en) * | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
| KR20150023904A (ko) | 2012-06-27 | 2015-03-05 | 버그 엘엘씨 | 전립선암의 진단 및 치료에서의 마커의 용도 |
| CN104781415A (zh) * | 2012-06-28 | 2015-07-15 | 卡尔德拉健康有限责任公司 | 用于诊断前列腺癌的靶向RNA-Seq的方法和材料 |
| WO2014012165A1 (en) | 2012-07-19 | 2014-01-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| US9200073B2 (en) | 2012-08-31 | 2015-12-01 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
| US9120841B2 (en) | 2012-09-28 | 2015-09-01 | Agency For Science, Technology And Research | Amphiphilic linear peptidepeptoid and hydrogel comprising the same |
| EP2908848B1 (en) * | 2012-10-22 | 2018-04-25 | University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group | Compositions and methods for regulating arterial tone |
| EP4223770A3 (en) | 2012-11-05 | 2023-10-18 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| HK1214830A1 (zh) | 2012-11-05 | 2016-08-05 | Foundation Medicine, Inc. | 新型ntrk1融合分子及其应用 |
| WO2014073708A1 (ja) * | 2012-11-06 | 2014-05-15 | 国立大学法人宮崎大学 | 新規ペプチドおよびその用途 |
| JP6196034B2 (ja) * | 2012-12-20 | 2017-09-13 | ライオン株式会社 | 高血糖リスク判定用マーカーペプチドおよびその用途 |
| AU2013364049A1 (en) * | 2012-12-21 | 2015-07-02 | The Regents Of The University Of California | TSPAN 33 is a candidate for antibody targeted therapy for the treatment of B cell Hodgkin lymphomas |
| SG2012096699A (en) * | 2012-12-31 | 2014-07-30 | Agency Science Tech & Res | Amphiphilic linear peptide/peptoid and hydrogel comprising the same |
| EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| WO2014136910A1 (ja) * | 2013-03-08 | 2014-09-12 | 国立大学法人大阪大学 | ペリオスチンのＥｘｏｎ－２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物 |
| WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| TWI522367B (zh) * | 2013-04-12 | 2016-02-21 | Univ Chang Gung | Urine biomarkers are used to predict bladder and kidney cancer |
| WO2014175375A1 (ja) * | 2013-04-25 | 2014-10-30 | 国立大学法人宮崎大学 | 成人ｔ細胞白血病の診断方法および成人ｔ細胞白血病の治療薬のスクリーニング方法 |
| WO2014186809A2 (en) * | 2013-05-17 | 2014-11-20 | The Translational Genomics Research Institute | A genetic test to predict patient response to bone morphogenetic protein in arthrodesis |
| CN103319571B (zh) * | 2013-05-30 | 2015-04-08 | 北京正旦国际科技有限责任公司 | 一种鼻咽癌放疗敏感性多肽标志物spg03及其elisa试剂盒 |
| WO2014190422A1 (en) * | 2013-05-30 | 2014-12-04 | Genesis Group Inc. | Methods and compositions for detecting progressive hearing loss |
| GB201310203D0 (en) * | 2013-06-07 | 2013-07-24 | Electrophoretics Ltd | Materials and methods relating to Alzheimer's disease |
| JP5952967B2 (ja) * | 2013-06-12 | 2016-07-13 | マルハニチロ株式会社 | ジペプチジルペプチダーゼｉｖ（ｄｐｐｉｖ）阻害ペプチド化合物、それを含有する組成物、及びその製造方法 |
| US20160175351A1 (en) * | 2013-06-24 | 2016-06-23 | Duke University | Cancer treatment |
| WO2014205507A1 (en) * | 2013-06-28 | 2014-12-31 | Newsouth Innovations Pty Limited | Diagnostic method |
| CN110964796B (zh) | 2013-08-28 | 2024-04-05 | 贝克顿迪金森公司 | 大规模平行单细胞分析 |
| CA3222465A1 (en) | 2013-08-30 | 2015-03-05 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| ES2804510T3 (es) | 2013-10-04 | 2021-02-08 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión del gen ALAS1 |
| HUE055190T2 (hu) | 2013-10-11 | 2021-12-28 | Oxford Bio Therapeutics Ltd | Konjugált antitestek LY75 elleni rák kezelésére |
| AU2014335720B2 (en) | 2013-10-18 | 2019-08-01 | Universidade Do Minho | Peptide composition and uses thereof |
| IL229134A0 (en) * | 2013-10-29 | 2014-03-31 | Omrix Biopharmaceuticals Ltd | Compounds and methods for stabilizing thrombin activity |
| CN106029874B (zh) | 2013-12-16 | 2020-09-15 | 北卡罗来纳-查佩尔山大学 | 浆细胞样树突状细胞的耗竭 |
| EP3092252B1 (en) | 2014-01-08 | 2019-09-18 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Antibody targeting cell surface deposited complement protein c3d and use thereof |
| CN103756984B (zh) * | 2014-02-18 | 2015-10-14 | 吉林大学 | 高活力谷胱甘肽过氧化物酶gpx2突变体及其制备方法 |
| US10520494B2 (en) | 2014-03-26 | 2019-12-31 | Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Flattop (FLTP) is a novel biomarker for beta cell maturation |
| US10927384B2 (en) | 2014-04-09 | 2021-02-23 | Dna Twopointo Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
| WO2015158006A1 (zh) * | 2014-04-18 | 2015-10-22 | 烟台聚杰生物工程有限公司 | 15种男性生育相关蛋白或其组合的应用 |
| ES2955736T3 (es) | 2014-05-06 | 2023-12-05 | Hoffmann La Roche | Producción de proteínas heteromultiméricas usando células de mamífero |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| GB201409519D0 (en) * | 2014-05-29 | 2014-07-16 | Univ Leicester | Senescent cell biomarkers |
| WO2015187992A2 (en) * | 2014-06-05 | 2015-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| CN105879053A (zh) * | 2014-09-26 | 2016-08-24 | 北京大学 | Cmtm1-v5基因及其编码蛋白的应用 |
| US10035823B2 (en) | 2014-09-29 | 2018-07-31 | The Regents Of The University Of California | Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions |
| WO2016054075A1 (en) * | 2014-09-29 | 2016-04-07 | University Of Rochester | U2af65 variants and uses thereof |
| ES2568702B1 (es) * | 2014-10-01 | 2017-02-13 | Servizo Galego De Saude (Sergas) | Método para el diagnóstico de artrosis |
| US10745736B2 (en) | 2014-10-01 | 2020-08-18 | Centre For Addiction And Mental Health | Markers for mood disorders |
| CN104225088A (zh) * | 2014-10-06 | 2014-12-24 | 李先强 | 治疗慢性肺心病的混合中药 |
| SG11201704660YA (en) | 2014-12-08 | 2017-07-28 | Berg Llc | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
| KR20170095284A (ko) * | 2014-12-09 | 2017-08-22 | 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 | 종양 항원 펩티드 |
| JP2018502566A (ja) * | 2014-12-12 | 2018-02-01 | タフツ ユニバーシティー | コラゲナーゼ由来ペプチドは組織再生および創傷治癒を促進する。 |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| HRP20211754T1 (hr) | 2014-12-23 | 2022-03-04 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| CN104673762B (zh) * | 2015-01-19 | 2017-10-20 | 江苏大学 | 抗泛素连接酶Nedd4‑1的特异性抗体及其应用 |
| CN105985423A (zh) * | 2015-01-30 | 2016-10-05 | 天津奥维亚生物技术有限公司 | 一种人c1qb多肽及其抗体制备方法 |
| WO2016123628A1 (en) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of Colorado, A Body Corporate | Sequence specific and organism specific antimicrobials and related materials and methods |
| WO2016132393A1 (en) * | 2015-02-17 | 2016-08-25 | CESARENI, Gianni | Hybrid protein for the identification of neddylated substrates |
| CA2976926A1 (en) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
| DK3259597T3 (da) | 2015-02-19 | 2022-05-09 | Compugen Ltd | Pvrig-polypeptider og fremgangsmåder til behandling |
| EP3262192B1 (en) | 2015-02-27 | 2020-09-16 | Becton, Dickinson and Company | Spatially addressable molecular barcoding |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| PT3388075T (pt) | 2015-03-27 | 2023-08-18 | Immatics Biotechnologies Gmbh | Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores |
| WO2016160844A2 (en) | 2015-03-30 | 2016-10-06 | Cellular Research, Inc. | Methods and compositions for combinatorial barcoding |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| JP6833705B2 (ja) | 2015-04-03 | 2021-02-24 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
| WO2016172373A1 (en) | 2015-04-23 | 2016-10-27 | Cellular Research, Inc. | Methods and compositions for whole transcriptome amplification |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| CN114085283A (zh) | 2015-05-19 | 2022-02-25 | 拉·约拉过敏反应及免疫医学研究所 | 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途 |
| US11124823B2 (en) | 2015-06-01 | 2021-09-21 | Becton, Dickinson And Company | Methods for RNA quantification |
| ES2806498T3 (es) | 2015-06-08 | 2021-02-17 | Arquer Diagnostics Ltd | Métodos para el análisis de una muestra de orina |
| EP4060344A1 (en) | 2015-06-08 | 2022-09-21 | Arquer Diagnostics Limited | Methods and kits |
| MX393605B (es) * | 2015-06-26 | 2025-03-24 | Univ California | Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo |
| EP3115058A1 (fr) * | 2015-07-09 | 2017-01-11 | Institut Gustave Roussy | Peptides immunogenes de preprocalcitonine |
| ES3020458T3 (en) | 2015-08-07 | 2025-05-22 | Imaginab Inc | Antigen binding constructs to target molecules |
| EP3130680A1 (en) * | 2015-08-11 | 2017-02-15 | Universitat de Girona | Method for the detection, follow up and/or classification of intestinal diseases |
| IL257335B (en) * | 2015-08-12 | 2022-08-01 | Oncotherapy Science Inc | Depdc1-derived peptide and vaccine containing same |
| WO2017031342A1 (en) * | 2015-08-20 | 2017-02-23 | Rhode Island Hospital | Circulating biomarker for brugada syndrome |
| JP6757924B2 (ja) * | 2015-08-24 | 2020-09-23 | 国立大学法人 東京大学 | オキシトシン感受性予測マーカー |
| CN108026524A (zh) | 2015-09-11 | 2018-05-11 | 赛卢拉研究公司 | 用于核酸文库标准化的方法和组合物 |
| CN116440279A (zh) | 2015-09-17 | 2023-07-18 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| US11085932B2 (en) | 2015-10-08 | 2021-08-10 | Universite De Geneve | Periostin fragments and use thereof |
| EP3974524A1 (en) | 2015-10-08 | 2022-03-30 | Dna Twopointo Inc. | Dna vectors, transposons and transposases for eukaryotic genome modification |
| US10844109B2 (en) | 2015-10-16 | 2020-11-24 | Institut National Transfusion Sanguine | Method for producing erythrocyte proteins |
| JP7174627B2 (ja) | 2015-10-23 | 2022-11-17 | ウニフェルシタイト・トゥヴェンテ | インテグリン結合ペプチド及びその使用 |
| CA3005070A1 (en) * | 2015-11-11 | 2017-05-18 | Serimmune Inc. | Methods and compositions for assessing antibody specificities |
| ES2984663T3 (es) | 2015-11-13 | 2024-10-30 | Oasis Pharmaceuticals Llc | Moduladores del receptor 2 activados por proteasa |
| KR102877920B1 (ko) | 2015-11-16 | 2025-10-30 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법 |
| GB201520542D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201607534D0 (en) * | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| MY196837A (en) | 2015-12-11 | 2023-05-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| CN109072219B (zh) * | 2015-12-28 | 2024-02-27 | 北海道公立大学法人札幌医科大学 | 肿瘤抗原肽 |
| CN105622742B (zh) * | 2016-02-22 | 2019-01-18 | 西安交通大学 | 一种孤独症血清多肽标志物fabp1-a及其应用 |
| AU2017225758B2 (en) | 2016-03-02 | 2023-03-16 | Idexx Laboratories, Inc. | Methods and compositions for the detection and diagnosis of renal disease and periodontal disease |
| PE20181896A1 (es) | 2016-04-06 | 2018-12-11 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide agua (lma) y otros tipos de cancer |
| HUE066442T2 (hu) | 2016-04-15 | 2024-08-28 | Res Institute At Nationwide | ß-szarkoglikán és mikroRNS-29 adenoasszociáltvírus-vektorral történõ bejuttatása és izomdisztrófia kezelése |
| EP4269616A3 (en) | 2016-05-02 | 2024-02-14 | Becton, Dickinson and Company | Accurate molecular barcoding |
| WO2017190218A1 (en) * | 2016-05-06 | 2017-11-09 | University Health Network | Liquid-biopsy signatures for prostate cancer |
| US10301677B2 (en) | 2016-05-25 | 2019-05-28 | Cellular Research, Inc. | Normalization of nucleic acid libraries |
| US10202641B2 (en) | 2016-05-31 | 2019-02-12 | Cellular Research, Inc. | Error correction in amplification of samples |
| US10640763B2 (en) | 2016-05-31 | 2020-05-05 | Cellular Research, Inc. | Molecular indexing of internal sequences |
| CA2971303A1 (en) | 2016-06-21 | 2017-12-21 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| US20240002459A1 (en) * | 2016-07-14 | 2024-01-04 | Emory University | Granulin Compositions and Uses Related Thereto |
| IL301682B2 (en) | 2016-08-17 | 2025-06-01 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
| TWI796299B (zh) | 2016-08-26 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| AU2017331361B2 (en) | 2016-09-23 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof |
| KR102638006B1 (ko) | 2016-09-26 | 2024-02-20 | 셀룰러 리서치, 인크. | 바코딩된 올리고뉴클레오티드 서열을 갖는 시약을 이용한 단백질 발현의 측정 |
| JP2020503840A (ja) | 2016-10-07 | 2020-02-06 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | Ｈｌａ拘束性ｖｇｌｌ１ペプチドおよびその使用 |
| US11981943B2 (en) | 2016-10-11 | 2024-05-14 | University Of Iowa Research Foundation | Methods and composition for detecting CAPN5 |
| EP3450453A4 (en) * | 2016-12-27 | 2019-05-01 | Zhejiang University | LEG1 PROTEIN, LEG1 GEN, APPLICATIONS OF LEG1 PROTEIN AND LEG1 GENE AND MEDICAMENTS |
| US11319583B2 (en) | 2017-02-01 | 2022-05-03 | Becton, Dickinson And Company | Selective amplification using blocking oligonucleotides |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| JP7247099B2 (ja) * | 2017-03-31 | 2023-03-28 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ヒト血清または尿におけるａｌｘｎ１２１０およびエクリズマブの同時定量のための方法 |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| US11531030B2 (en) * | 2017-04-21 | 2022-12-20 | Mayo Foundation For Medical Education And Research | Polypeptide-antibody complexes and uses thereof |
| CN110892062A (zh) | 2017-05-05 | 2020-03-17 | 佛罗里达大学研究基金会 | 表达耳畸蛋白的组合物和方法 |
| CN110799213A (zh) | 2017-06-01 | 2020-02-14 | 康姆普根有限公司 | 三联组合抗体疗法 |
| EP4345172A3 (en) | 2017-06-05 | 2024-07-03 | Becton, Dickinson and Company | Sample indexing for single cells |
| WO2018225830A1 (ja) * | 2017-06-08 | 2018-12-13 | 国立大学法人宮崎大学 | 肺がんの検出方法 |
| WO2019006022A1 (en) * | 2017-06-27 | 2019-01-03 | The Broad Institute, Inc. | SYSTEMS AND METHODS FOR PREDICTING MHC CLASS II EPITOPE |
| CN107326090B (zh) * | 2017-08-23 | 2020-05-26 | 武汉大学 | 用于非小细胞肺癌诊断的血小板LncRNA的定量检测方法 |
| ES2702617B2 (es) * | 2017-09-04 | 2019-11-18 | Univ Rovira I Virgili | Hidrolizados de garras de patas de pollo, sus péptidos y usos de los mismos |
| KR102034929B1 (ko) * | 2017-09-27 | 2019-10-22 | 한양대학교 산학협력단 | Nckap1 단백질 또는 상기 단백질을 암호화하는 유전자를 포함하는 신경계 퇴행성질환의 예방 또는 치료용 약학적 조성물 |
| US11441122B2 (en) | 2017-10-05 | 2022-09-13 | Epivax Inc. | Regulatory T cell epitopes |
| CN107641626B (zh) * | 2017-11-23 | 2018-06-01 | 黄志清 | 912位点发生突变的RanBP9突变基因及其应用 |
| WO2019117690A1 (ko) * | 2017-12-15 | 2019-06-20 | 경북대학교 산학협력단 | Pd-l1에 결합하는 펩타이드 및 이의 용도 |
| US11946095B2 (en) | 2017-12-19 | 2024-04-02 | Becton, Dickinson And Company | Particles associated with oligonucleotides |
| KR20250097989A (ko) * | 2017-12-28 | 2025-06-30 | 그릿스톤 바이오, 인코포레이티드 | 공통 항원을 표적화하는 항원-결합 단백질 |
| JP2021510539A (ja) * | 2018-01-16 | 2021-04-30 | シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置 |
| CN108409851B (zh) * | 2018-01-29 | 2020-12-08 | 上海交通大学 | 肾细胞癌中高水平表达的蛋白及其应用 |
| SG11202006722RA (en) | 2018-01-31 | 2020-08-28 | Res Inst Nationwide Childrens Hospital | Gene therapy for limb-girdle muscular dystrophy type 2c |
| US20210238690A1 (en) * | 2018-04-26 | 2021-08-05 | Intellexon Gmbh | Hla-j and medical/diagnostic uses thereof |
| AU2019262048B2 (en) | 2018-05-03 | 2025-09-04 | Becton, Dickinson And Company | High throughput multiomics sample analysis |
| EP4545647A3 (en) | 2018-05-03 | 2025-07-09 | Becton, Dickinson and Company | Molecular barcoding on opposite transcript ends |
| TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| KR20210028162A (ko) | 2018-06-29 | 2021-03-11 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법 |
| AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
| US11712410B2 (en) | 2018-09-05 | 2023-08-01 | K18, Inc. | Composition for improving hair health |
| CN118853827A (zh) | 2018-10-01 | 2024-10-29 | 贝克顿迪金森公司 | 确定5’转录物序列 |
| US12422440B2 (en) | 2018-10-05 | 2025-09-23 | Seattle Children's Hospital | Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease |
| WO2020093018A1 (en) | 2018-11-01 | 2020-05-07 | University Of Florida Research Foundation, Incorporated | A codon optimized otoferlin aav dual vector gene therapy |
| CN112969789A (zh) | 2018-11-08 | 2021-06-15 | 贝克顿迪金森公司 | 使用随机引发的单细胞全转录组分析 |
| MX2021005757A (es) | 2018-11-15 | 2021-08-11 | Quantum Si Inc | Metodos y composiciones para la secuenciacion de proteinas. |
| EP3894552A1 (en) | 2018-12-13 | 2021-10-20 | Becton, Dickinson and Company | Selective extension in single cell whole transcriptome analysis |
| CN109456968B (zh) * | 2018-12-29 | 2022-10-04 | 上海奕谱生物科技有限公司 | 基于甲基化修饰的肿瘤标记物 |
| CN109651500B (zh) * | 2019-01-15 | 2021-08-13 | 南京蜂瑞生物科技有限公司 | 一种具有抑制白血病细胞增殖作用的多肽 |
| WO2020150356A1 (en) | 2019-01-16 | 2020-07-23 | Becton, Dickinson And Company | Polymerase chain reaction normalization through primer titration |
| EP3914728B1 (en) | 2019-01-23 | 2023-04-05 | Becton, Dickinson and Company | Oligonucleotides associated with antibodies |
| WO2020163743A1 (en) | 2019-02-08 | 2020-08-13 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| EP3695883A1 (en) * | 2019-02-13 | 2020-08-19 | Alytas Therapeutics GmbH | Means for specifically eliminating perilipin-1 fragment presenting adipocytes |
| CN113454234B (zh) | 2019-02-14 | 2025-03-18 | 贝克顿迪金森公司 | 杂合体靶向和全转录物组扩增 |
| AU2020225319B2 (en) * | 2019-02-19 | 2025-05-29 | Medizinische Universität Wien | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine |
| CA3131390A1 (en) | 2019-02-26 | 2020-09-03 | Research Institute Of Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy |
| SG11202110607WA (en) | 2019-04-01 | 2021-10-28 | Tenaya Therapeutics Inc | Adeno-associated virus with engineered capsid |
| CN110045130B (zh) * | 2019-04-17 | 2022-03-29 | 中山大学附属第一医院 | 一种与IgA肾病相关的多肽的免疫分析检测试剂盒 |
| WO2021007473A1 (en) | 2019-07-10 | 2021-01-14 | Masonic Medical Research Institute | Vgll4 with ucp-1 cis-regulatory element and method of use thereof |
| WO2021011660A1 (en) * | 2019-07-15 | 2021-01-21 | Oncocyte Corporation | Methods and compositions for detection and treatment of lung cancer |
| EP4004231B1 (en) | 2019-07-22 | 2025-11-12 | Becton, Dickinson and Company | Single cell chromatin immunoprecipitation sequencing assay |
| HRP20240505T1 (hr) | 2019-08-21 | 2024-07-05 | Research Institute At Nationwide Children's Hospital | Dostava alfa-sarkoglikana vektorom povezanim s adenovirusom i liječenje mišićne distrofije |
| WO2021050510A1 (en) * | 2019-09-09 | 2021-03-18 | The Wistar Institute Of Anatomy And Biology | Engineered peptide and peptide mimetic compositions and methods |
| CN110706749B (zh) * | 2019-09-10 | 2022-06-10 | 至本医疗科技（上海）有限公司 | 一种基于组织器官分化层次关系的癌症类型预测系统和方法 |
| US20220347279A1 (en) * | 2019-10-03 | 2022-11-03 | Board Of Regents, The University Of Texas System | Vcx/y peptides and use thereof |
| CN110669104B (zh) * | 2019-10-30 | 2021-11-05 | 上海交通大学 | 一组来源于人外周血单核细胞的标志物及其应用 |
| CN114729350A (zh) | 2019-11-08 | 2022-07-08 | 贝克顿迪金森公司 | 使用随机引发获得用于免疫组库测序的全长v(d)j信息 |
| US11649497B2 (en) | 2020-01-13 | 2023-05-16 | Becton, Dickinson And Company | Methods and compositions for quantitation of proteins and RNA |
| CN115003692B (zh) * | 2020-01-19 | 2024-09-03 | 北京生命科学研究所 | 乙型肝炎病毒感染的特异性宿主因子及其应用 |
| EP4097228B1 (en) | 2020-01-29 | 2024-08-14 | Becton, Dickinson and Company | Barcoded wells for spatial mapping of single cells through sequencing |
| CA3168917A1 (en) * | 2020-01-31 | 2021-08-05 | Venn Biosciences Corporation | Biomarkers for diagnosing ovarian cancer |
| EP3868884A1 (en) * | 2020-02-19 | 2021-08-25 | Aarhus Universitet | Method for subtyping bladder cancer using aptamers |
| WO2021173719A1 (en) | 2020-02-25 | 2021-09-02 | Becton, Dickinson And Company | Bi-specific probes to enable the use of single-cell samples as single color compensation control |
| KR20210121585A (ko) * | 2020-03-30 | 2021-10-08 | 한국세라믹기술원 | 반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법 |
| US11940448B2 (en) | 2020-03-31 | 2024-03-26 | Seattle Children's Hospital | Proteomic screening for lysosomal storage diseases |
| CN115666658A (zh) | 2020-04-01 | 2023-01-31 | 佛罗里达州大学研究基金会 | 具有提高的治疗ush1b的安全性的双aav-myo7a载体 |
| IT202000006973A1 (it) * | 2020-04-02 | 2021-10-02 | Istituto Naz Tumori Irccs Fondazione G Pascale | Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro |
| EP4146237A4 (en) * | 2020-05-04 | 2024-11-13 | University of Utah | IMMUNOTHROMBOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME OF COVID-19 |
| EP4150118A1 (en) | 2020-05-14 | 2023-03-22 | Becton Dickinson and Company | Primers for immune repertoire profiling |
| JP2023527764A (ja) * | 2020-05-20 | 2023-06-30 | クアンタム－エスアイ インコーポレイテッド | タンパク質シーケンスのための方法及び組成物 |
| WO2021247487A1 (en) * | 2020-06-01 | 2021-12-09 | Medical University Of South Carolina | Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders |
| EP4407030B1 (en) | 2020-06-02 | 2025-12-17 | Becton, Dickinson and Company | Oligonucleotides and beads for 5 prime gene expression assay |
| TW202216111A (zh) | 2020-07-03 | 2022-05-01 | 米尼奧大學 | 香氛釋放機制、方法及其用途 |
| US11932901B2 (en) | 2020-07-13 | 2024-03-19 | Becton, Dickinson And Company | Target enrichment using nucleic acid probes for scRNAseq |
| CN116194589A (zh) | 2020-07-31 | 2023-05-30 | 贝克顿迪金森公司 | 用于转座酶可及染色质的单细胞测定 |
| US20240180166A1 (en) * | 2020-08-03 | 2024-06-06 | Cornell University | Keratinolytic polypeptides and methods of use |
| AU2021355481A1 (en) * | 2020-10-01 | 2023-06-08 | Genzyme Corporation | Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy |
| US11781156B2 (en) * | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2022109343A1 (en) | 2020-11-20 | 2022-05-27 | Becton, Dickinson And Company | Profiling of highly expressed and lowly expressed proteins |
| US12392771B2 (en) | 2020-12-15 | 2025-08-19 | Becton, Dickinson And Company | Single cell secretome analysis |
| CN112552394B (zh) * | 2020-12-30 | 2023-03-21 | 青海瑞肽生物科技有限公司 | 一种牦牛降压肽及其制备方法 |
| CN113061176B (zh) * | 2021-03-12 | 2022-08-16 | 华中农业大学 | 一种草鱼抗菌蛋白lect2及其制备方法和应用 |
| KR20220142954A (ko) * | 2021-04-15 | 2022-10-24 | 한국생명공학연구원 | 세포 투과 펩티드, 항암 펩티드 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| CN117597364A (zh) * | 2021-05-12 | 2024-02-23 | 百进生物科技公司 | 抗ccr8抗体、其抗原结合片段、以及试剂和组合物及其制备和使用方法 |
| WO2023049541A1 (en) * | 2021-07-23 | 2023-03-30 | Cassava Sciences, Inc. | Blood-based diagnostic assays for alzheimer's disease |
| TWI800922B (zh) * | 2021-09-14 | 2023-05-01 | 東海大學 | 短胜肽、含有該短胜肽之水解物及其用於預防或/及治療神經損傷相關疾病之用途 |
| TWI838648B (zh) * | 2021-09-28 | 2024-04-11 | 臺北醫學大學 | 用於檢測大腸直腸癌的組合物的用途與方法 |
| WO2023060186A1 (en) * | 2021-10-07 | 2023-04-13 | Hepatx Corporation | Methods of tracking donor cells in a recipient |
| EP4219726A1 (en) | 2021-10-15 | 2023-08-02 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
| CN114195884B (zh) * | 2021-10-27 | 2024-03-29 | 禾美生物科技(浙江)有限公司 | 一种重组人源胶原蛋白及其制备方法 |
| GB2621640A (en) * | 2021-11-10 | 2024-02-21 | Univ South China Tech | Active polypeptide for inhibiting growth of liver cancer cells, and preparation method therefor and use thereof |
| CN113845571B (zh) * | 2021-11-10 | 2023-08-15 | 华南理工大学 | 一种抑制肝癌细胞生长的活性多肽及其制备方法和应用 |
| EP4433591A1 (en) * | 2021-11-18 | 2024-09-25 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating progranulin expression |
| AU2022399828A1 (en) * | 2021-11-30 | 2024-05-23 | Venn Biosciences Corporation | Diagnosis of pancreatic cancer using targeted quantification of site-specific protein glycosylation |
| WO2023196898A1 (en) * | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
| TWI845024B (zh) * | 2022-11-15 | 2024-06-11 | 長庚大學 | 用以診斷和預斷大腸直腸癌的方法 |
| WO2024115743A1 (en) * | 2022-12-02 | 2024-06-06 | Cézanne S.A.S. | Protein biomarkers for use in methods for the diagnosis or prognosis of chronic airflow limitation (cal) and chronic obstructive pulmonary disease (copd) |
| CN115894623B (zh) * | 2022-12-20 | 2025-05-13 | 中国科学院昆明动物研究所 | 一种具有双重调节dbh和ddc酶活性功能的多肽nr6及其应用 |
| CN116891523B (zh) * | 2023-05-24 | 2024-05-17 | 深圳晶蛋生物医药科技有限公司 | 一种trpm3截短体、包含其的细胞系及其用途 |
| WO2025003457A1 (en) * | 2023-06-29 | 2025-01-02 | University Of Fribourg | Targeted proteomics for monitoring autophagy |
| KR20250031017A (ko) * | 2023-08-23 | 2025-03-06 | 재단법인 아산사회복지재단 | Pibf1 또는 이를 코딩하는 유전자를 포함하는 벡터를 포함하는 태반 또는 태아 심혈관 이상과 관련된 임신 합병증의 예방 또는 치료용 약학 조성물 |
| CN119899273B (zh) * | 2025-01-15 | 2025-10-31 | 中国人民解放军空军军医大学 | 一种人pgk1第131位赖氨酸乳酸化修饰的抗体制备方法与应用 |
Family Cites Families (272)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US493495A (en) | 1893-03-14 | Lantern | ||
| US604823A (en) | 1898-05-31 | Op stratiidon | ||
| US197506A (en) | 1877-11-27 | Improvement in hernia-trusses | ||
| US4437975A (en) | 1977-07-20 | 1984-03-20 | Mobil Oil Corporation | Manufacture of lube base stock oil |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4690715A (en) | 1982-06-18 | 1987-09-01 | American Telephone And Telegraph Company, At&T Bell Laboratories | Modification of the properties of metals |
| WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4483105A (en) | 1983-03-11 | 1984-11-20 | Maschinenfabrik Gehring, Gesellschaft Mit Beschrankter Haftung & Co. Kommanditgesellschaft | Device to hold workpieces for the honing of their axial center bore |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4644545A (en) | 1983-05-16 | 1987-02-17 | Data General Corporation | Digital encoding and decoding apparatus |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5242794A (en) | 1984-12-13 | 1993-09-07 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US5333675C1 (en) | 1986-02-25 | 2001-05-01 | Perkin Elmer Corp | Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| WO1986005803A1 (fr) | 1985-03-30 | 1986-10-09 | Marc Ballivet | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| US4886743A (en) * | 1985-04-24 | 1989-12-12 | California Institute Of Technology | Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof |
| US5045995A (en) | 1985-06-24 | 1991-09-03 | Vicom Systems, Inc. | Selective operation of processing elements in a single instruction multiple data stream (SIMD) computer system |
| US4965108A (en) | 1985-09-11 | 1990-10-23 | First Brands Corporation | Low temperature impact and puncture resistant thermoplastic films and bags therefrom |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Methods and kits for amplification and testing of nucleic acid sequences |
| US4833195A (en) | 1987-07-20 | 1989-05-23 | Bp Performance Polymers, Inc. | High flow drapable polymer compositions |
| CA1340843C (en) | 1987-07-31 | 1999-12-07 | J. Lawrence Burg | Selective amplification of target polynucleotide sequences |
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| JP2650159B2 (ja) | 1988-02-24 | 1997-09-03 | アクゾ・ノベル・エヌ・ベー | 核酸増幅方法 |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US4988617A (en) | 1988-03-25 | 1991-01-29 | California Institute Of Technology | Method of detecting a nucleotide change in nucleic acids |
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| KR0148265B1 (ko) | 1988-12-16 | 1998-10-15 | 에프.지이.엠 헤르만스 | 자가-지속 서열 복제 시스템 |
| US5856092A (en) | 1989-02-13 | 1999-01-05 | Geneco Pty Ltd | Detection of a nucleic acid sequence or a change therein |
| US5081584A (en) | 1989-03-13 | 1992-01-14 | United States Of America | Computer-assisted design of anti-peptides based on the amino acid sequence of a target peptide |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5871928A (en) | 1989-06-07 | 1999-02-16 | Fodor; Stephen P. A. | Methods for nucleic acid analysis |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US6346413B1 (en) | 1989-06-07 | 2002-02-12 | Affymetrix, Inc. | Polymer arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US6309822B1 (en) | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| ATE282716T1 (de) | 1989-07-11 | 2004-12-15 | Gen Probe Inc | Verfahren zur amplifikation von nukleinsäuresequenzen |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5494810A (en) | 1990-05-03 | 1996-02-27 | Cornell Research Foundation, Inc. | Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| AU8840091A (en) | 1990-08-24 | 1992-03-17 | University Of Tennessee Research Corporation, The | Dna amplification fingerprinting |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| CA2027434C (en) * | 1990-10-12 | 1999-01-05 | George Jackowski | Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof |
| WO1992007095A1 (en) | 1990-10-15 | 1992-04-30 | Stratagene | Arbitrarily primed polymerase chain reaction method for fingerprinting genomes |
| JP3523252B2 (ja) | 1990-11-21 | 2004-04-26 | ホウテン ファーマシューティカルズ インコーポレイテッド | 等モル多種オリゴマー混合物、特にオリゴペプチド混合物の合成 |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| AU675054B2 (en) | 1991-11-22 | 1997-01-23 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5550215A (en) | 1991-11-22 | 1996-08-27 | Holmes; Christopher P. | Polymer reversal on solid surfaces |
| IT1252624B (it) | 1991-12-05 | 1995-06-19 | Cons Ric Microelettronica | Dispositivo semiconduttore incapsulato in resina e elettricamente isolato di migliorate caratteristiche di isolamento,e relativo processo di fabbricazione |
| US5346994A (en) | 1992-01-28 | 1994-09-13 | Piotr Chomczynski | Shelf-stable product and process for isolating RNA, DNA and proteins |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| CA2064683A1 (en) | 1992-03-26 | 1993-09-27 | Krishna Mohan Rao Kallury | Formation of thermostable enzymes with extra-ordinary heat tolerance by immobilization on phospholipid matrices |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| GB9208733D0 (en) | 1992-04-22 | 1992-06-10 | Medical Res Council | Dna sequencing method |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| FR2703359B1 (fr) | 1993-03-31 | 1995-06-23 | Cis Bio Int | Copolymère nucléotide(s)/polymère conducteur électronique ; son procédé de préparation et son utilisation . |
| US5491074A (en) | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
| US5312790A (en) | 1993-06-09 | 1994-05-17 | The United States Of America As Represented By The Secretary Of The Army | Ceramic ferroelectric material |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| AU7212494A (en) | 1993-06-25 | 1995-01-17 | Affymax Technologies N.V. | Hybridization and sequencing of nucleic acids |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| ATE208658T1 (de) | 1993-07-28 | 2001-11-15 | Pe Corp Ny | Vorrichtung und verfahren zur nukleinsäurevervielfältigung |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| US5429708A (en) | 1993-12-22 | 1995-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular layers covalently bonded to silicon surfaces |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US6090555A (en) | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
| JP3552264B2 (ja) | 1994-03-04 | 2004-08-11 | ヤマハ株式会社 | 自動演奏装置 |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| DE69503126T2 (de) | 1994-05-05 | 1998-11-12 | Beckman Instruments Inc | Repetitive oligonukleotide matrix |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| WO1995034683A1 (en) | 1994-06-10 | 1995-12-21 | Symbiotech, Inc. | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
| US5403464A (en) | 1994-06-15 | 1995-04-04 | Modern Controls, Inc. | High permeability rate oxygen sensor |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5627024A (en) | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
| US5620850A (en) | 1994-09-26 | 1997-04-15 | President And Fellows Of Harvard College | Molecular recognition at surfaces derivatized with self-assembled monolayers |
| US5695934A (en) | 1994-10-13 | 1997-12-09 | Lynx Therapeutics, Inc. | Massively parallel sequencing of sorted polynucleotides |
| US6013445A (en) | 1996-06-06 | 2000-01-11 | Lynx Therapeutics, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
| US5846719A (en) | 1994-10-13 | 1998-12-08 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
| US5545539A (en) | 1994-10-18 | 1996-08-13 | Genzyme Corporation | Method for nucleotide sequence amplification |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5688642A (en) | 1994-12-01 | 1997-11-18 | The United States Of America As Represented By The Secretary Of The Navy | Selective attachment of nucleic acid molecules to patterned self-assembled surfaces |
| EP1241264A1 (en) | 1994-12-02 | 2002-09-18 | Chiron Corporation | Monoclonal antibodies to colon cancer antigen |
| NO179986C (no) | 1994-12-08 | 1997-01-22 | Norske Stats Oljeselskap | Fremgangsmåte og system for fremstilling av flytendegjort naturgass til havs |
| US6270962B1 (en) | 1995-01-30 | 2001-08-07 | The Regents Of The University Of California | Methods for the elimination of DNA sequencing artifacts |
| US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
| US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| WO1996038726A1 (en) | 1995-05-30 | 1996-12-05 | Ecole Polytechnique Federale De Lausanne (Epfl) | Covalently immobilized phospholipid bilayers on solid surfaces |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| US5671894A (en) | 1995-08-11 | 1997-09-30 | Alliedsignal Inc. | Retractor with load limiting spool with decoupled pretensioner |
| DK0854933T3 (da) | 1995-09-07 | 2003-07-21 | Novozymes As | Fagfremvisning for detergentenzym aktivitet |
| US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
| EP0852004B1 (en) | 1995-10-11 | 2011-01-19 | Luminex Corporation | Multiplexed analysis of clinical specimens |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
| US6063026A (en) * | 1995-12-07 | 2000-05-16 | Carbon Based Corporation | Medical diagnostic analysis system |
| US6147205A (en) | 1995-12-15 | 2000-11-14 | Affymetrix, Inc. | Photocleavable protecting groups and methods for their use |
| EP0914335A2 (en) * | 1996-03-15 | 1999-05-12 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
| ES2229347T3 (es) | 1996-03-20 | 2005-04-16 | Dyax Corp. | Purificacion del activador del plasminogeno tisular tpa. |
| US6114122A (en) | 1996-03-26 | 2000-09-05 | Affymetrix, Inc. | Fluidics station with a mounting system and method of using |
| JP2000512744A (ja) | 1996-05-16 | 2000-09-26 | アフィメトリックス，インコーポレイテッド | 標識材料を検出するシステムおよび方法 |
| JP2000512981A (ja) | 1996-06-06 | 2000-10-03 | ラ ホヤ ファーマシューティカル カンパニー | ａＰＬ免疫応答性ペプチド、その結合体およびａＰＬ抗体媒介病理のための処置方法 |
| JP2880453B2 (ja) | 1996-06-07 | 1999-04-12 | 三桜工業株式会社 | 配管用継手装置のリテーナ |
| AU735015B2 (en) | 1996-06-10 | 2001-06-28 | Scripps Research Institute, The | Use of substrate subtraction libraries to distinguish enzyme specificities |
| US5766905A (en) | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| EP0912767B1 (en) | 1996-07-16 | 2006-09-13 | Gen-Probe Incorporated | Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific tm |
| WO1998014277A1 (en) | 1996-10-04 | 1998-04-09 | Whatman, Inc. | Device and method for simultaneous multiple chemical syntheses |
| CA2267139A1 (en) | 1996-10-08 | 1998-04-16 | Ton Logtenberg | Methods and means for selecting peptides and proteins having specific affinity for a target |
| AU745101B2 (en) | 1996-11-06 | 2002-03-14 | Genentech Inc. | Constrained helical peptides and methods of making same |
| DE69727489T2 (de) | 1996-11-06 | 2004-11-25 | Sequenom, Inc., San Diego | Verfahren zur massenspektrometrie |
| IL119587A (en) | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
| IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
| US6025681A (en) | 1997-02-05 | 2000-02-15 | Duly Research Inc. | Dielectric supported radio-frequency cavities |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6969488B2 (en) | 1998-05-22 | 2005-11-29 | Solexa, Inc. | System and apparatus for sequential processing of analytes |
| DE69833758T2 (de) | 1997-06-13 | 2006-08-31 | Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara | Verfahren zur erkennung von genpolymorphismen und allelexpression unter verwendung von sondenchips |
| US6333179B1 (en) | 1997-06-20 | 2001-12-25 | Affymetrix, Inc. | Methods and compositions for multiplex amplification of nucleic acids |
| US6172211B1 (en) * | 1997-07-11 | 2001-01-09 | Boehringer Ingelheim International Gmbh | Nucleic acid encoding tag7 polypeptide |
| US6420108B2 (en) | 1998-02-09 | 2002-07-16 | Affymetrix, Inc. | Computer-aided display for comparative gene expression |
| WO1999005591A2 (en) | 1997-07-25 | 1999-02-04 | Affymetrix, Inc. | Method and apparatus for providing a bioinformatics database |
| US5878832A (en) | 1997-08-13 | 1999-03-09 | General Motors Corporation | Steering apparatus for motor vehicle |
| CA2299625A1 (en) | 1997-08-15 | 1999-02-25 | Affymetrix, Inc. | Polymorphism detection utilizing clustering analysis |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6124120A (en) | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US6013449A (en) | 1997-11-26 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Probe-based analysis of heterozygous mutations using two-color labelling |
| US6269846B1 (en) | 1998-01-13 | 2001-08-07 | Genetic Microsystems, Inc. | Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays |
| US6201639B1 (en) | 1998-03-20 | 2001-03-13 | James W. Overbeck | Wide field of view and high speed scanning microscopy |
| US6428752B1 (en) | 1998-05-14 | 2002-08-06 | Affymetrix, Inc. | Cleaning deposit devices that form microarrays and the like |
| US6185030B1 (en) | 1998-03-20 | 2001-02-06 | James W. Overbeck | Wide field of view and high speed scanning microscopy |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US5936324A (en) | 1998-03-30 | 1999-08-10 | Genetic Microsystems Inc. | Moving magnet scanner |
| US6525185B1 (en) | 1998-05-07 | 2003-02-25 | Affymetrix, Inc. | Polymorphisms associated with hypertension |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6787308B2 (en) | 1998-07-30 | 2004-09-07 | Solexa Ltd. | Arrayed biomolecules and their use in sequencing |
| US6171239B1 (en) | 1998-08-17 | 2001-01-09 | Emory University | Systems, methods, and devices for controlling external devices by signals derived directly from the nervous system |
| US6185561B1 (en) | 1998-09-17 | 2001-02-06 | Affymetrix, Inc. | Method and apparatus for providing and expression data mining database |
| AR021833A1 (es) | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
| US6262216B1 (en) | 1998-10-13 | 2001-07-17 | Affymetrix, Inc. | Functionalized silicon compounds and methods for their synthesis and use |
| WO2000024939A1 (en) | 1998-10-27 | 2000-05-04 | Affymetrix, Inc. | Complexity management and analysis of genomic dna |
| US6252743B1 (en) | 1998-11-02 | 2001-06-26 | Read-Rite Corporation | Read/write positioning arm with interspaced amplifier chips |
| DE69940623D1 (de) | 1998-11-09 | 2009-04-30 | Eiken Chemical | Prozess zur Synthetisierung von Nukleinsäure |
| JP2002533726A (ja) | 1998-12-28 | 2002-10-08 | サネシス ファーマシューティカルス インコーポレイテッド | 結合のための小有機分子リガンドの同定 |
| US6470305B1 (en) | 1998-12-31 | 2002-10-22 | Ajay N. Jain | Chemical analysis by morphological similarity |
| US20060134637A1 (en) | 1999-01-06 | 2006-06-22 | Chondrogene Limited | Method for the detection of cancer related gene transcripts in blood |
| US6492505B1 (en) * | 1999-02-01 | 2002-12-10 | Incyte Genomics, Inc. | Composition for detection of genes encoding membrane-associated proteins |
| US6177248B1 (en) | 1999-02-24 | 2001-01-23 | Affymetrix, Inc. | Downstream genes of tumor suppressor WT1 |
| EP1165839A2 (en) | 1999-03-26 | 2002-01-02 | Whitehead Institute For Biomedical Research | Universal arrays |
| US6268141B1 (en) | 1999-05-12 | 2001-07-31 | Beckman Coulter, Inc. | Immobilization of unmodified biopolymers to acyl fluoride activated substrates |
| US6026601A (en) | 1999-05-25 | 2000-02-22 | Kiel; Walter J. | Ironing board adapted to vertical surface |
| US6300070B1 (en) | 1999-06-04 | 2001-10-09 | Mosaic Technologies, Inc. | Solid phase methods for amplifying multiple nucleic acids |
| US6218803B1 (en) | 1999-06-04 | 2001-04-17 | Genetic Microsystems, Inc. | Position sensing with variable capacitance transducers |
| EP1218543A2 (en) | 1999-09-29 | 2002-07-03 | Solexa Ltd. | Polynucleotide sequencing |
| US6958225B2 (en) | 1999-10-27 | 2005-10-25 | Affymetrix, Inc. | Complexity management of genomic DNA |
| DE19957827C2 (de) | 1999-11-25 | 2003-06-12 | Epigenomics Ag | Verwendung eines Oligomer-Arrays mit PNA- und/oder DNA-Oligomeren auf einer Oberfläche |
| EP1642909A3 (en) * | 1999-12-06 | 2006-04-12 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof |
| US6582938B1 (en) | 2001-05-11 | 2003-06-24 | Affymetrix, Inc. | Amplification of nucleic acids |
| US20030097222A1 (en) | 2000-01-25 | 2003-05-22 | Craford David M. | Method, system, and computer software for providing a genomic web portal |
| JP3490368B2 (ja) | 2000-02-07 | 2004-01-26 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 信号出力装置、ドライバ回路、信号伝送システム、および信号伝送方法 |
| US6267152B1 (en) | 2000-02-18 | 2001-07-31 | Wisconsin Label Corporation | Hang tag and method of applying hang tag to an elongated object |
| US6696620B2 (en) | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
| US6593425B2 (en) | 2000-05-31 | 2003-07-15 | General Electric Company | Data storage media containing transparent polycarbonate blends |
| US6531283B1 (en) | 2000-06-20 | 2003-03-11 | Molecular Staging, Inc. | Protein expression profiling |
| US20060166227A1 (en) | 2000-06-20 | 2006-07-27 | Stephen Kingsmore | Protein expression profiling |
| US6386749B1 (en) | 2000-06-26 | 2002-05-14 | Affymetrix, Inc. | Systems and methods for heating and mixing fluids |
| US6323009B1 (en) | 2000-06-28 | 2001-11-27 | Molecular Staging, Inc. | Multiply-primed amplification of nucleic acid sequences |
| US7567870B1 (en) * | 2000-07-31 | 2009-07-28 | Institute For Systems Biology | Multiparameter analysis for predictive medicine |
| JP2002071687A (ja) | 2000-08-31 | 2002-03-12 | Canon Inc | 変異遺伝子のスクリーニング方法 |
| WO2002027029A2 (en) | 2000-09-27 | 2002-04-04 | Lynx Therapeutics, Inc. | Method for determining relative abundance of nucleic acid sequences |
| EP1390523B1 (en) * | 2000-11-20 | 2007-05-09 | Eastern Virginia Medical School | Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers |
| US6391592B1 (en) | 2000-12-14 | 2002-05-21 | Affymetrix, Inc. | Blocker-aided target amplification of nucleic acids |
| US6448387B1 (en) | 2000-12-18 | 2002-09-10 | Monsanto Technology, Llc | Polymeric arrays adapted for high expressing polynucleotides |
| US6405783B1 (en) | 2000-12-23 | 2002-06-18 | Advanced Innovations, Llc. | Horizontal window blind apparatus |
| US20020183936A1 (en) | 2001-01-24 | 2002-12-05 | Affymetrix, Inc. | Method, system, and computer software for providing a genomic web portal |
| US20030120432A1 (en) | 2001-01-29 | 2003-06-26 | Affymetrix, Inc. | Method, system and computer software for online ordering of custom probe arrays |
| US6689568B2 (en) | 2001-02-01 | 2004-02-10 | Agilent Technologies, Inc. | Capture arrays using polypeptide capture agents |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US6777239B2 (en) | 2001-04-17 | 2004-08-17 | Xenoport, Inc. | Epitope-captured antibody display |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| US20030100995A1 (en) | 2001-07-16 | 2003-05-29 | Affymetrix, Inc. | Method, system and computer software for variant information via a web portal |
| US6632611B2 (en) | 2001-07-20 | 2003-10-14 | Affymetrix, Inc. | Method of target enrichment and amplification |
| US6872529B2 (en) | 2001-07-25 | 2005-03-29 | Affymetrix, Inc. | Complexity management of genomic DNA |
| US7343247B2 (en) | 2001-07-30 | 2008-03-11 | The Institute For Systems Biology | Methods of classifying drug responsiveness using multiparameter analysis |
| US7229774B2 (en) * | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20030044320A1 (en) | 2001-08-31 | 2003-03-06 | Shun Luo | High throughput screening micro array platform |
| US7057026B2 (en) | 2001-12-04 | 2006-06-06 | Solexa Limited | Labelled nucleotides |
| AU2002357147A1 (en) * | 2001-12-14 | 2003-06-30 | Incyte Genomics, Inc. | Transporters and ion channels |
| US20040002818A1 (en) | 2001-12-21 | 2004-01-01 | Affymetrix, Inc. | Method, system and computer software for providing microarray probe data |
| US7011945B2 (en) | 2001-12-21 | 2006-03-14 | Eastman Kodak Company | Random array of micro-spheres for the analysis of nucleic acids |
| US20030219801A1 (en) | 2002-03-06 | 2003-11-27 | Affymetrix, Inc. | Aptamer base technique for ligand identification |
| DE60332406D1 (de) | 2002-03-15 | 2010-06-17 | Affymetrix Inc | System und Verfahren zur Abtastung von biologischen Materialien |
| US20040049354A1 (en) | 2002-04-26 | 2004-03-11 | Affymetrix, Inc. | Method, system and computer software providing a genomic web portal for functional analysis of alternative splice variants |
| US20040126840A1 (en) | 2002-12-23 | 2004-07-01 | Affymetrix, Inc. | Method, system and computer software for providing genomic ontological data |
| US20070065816A1 (en) | 2002-05-17 | 2007-03-22 | Affymetrix, Inc. | Methods for genotyping |
| ATE469135T1 (de) | 2002-05-30 | 2010-06-15 | Scripps Research Inst | Kupferkatalysierte ligierung von aziden und acetylenen |
| AU2003249692B2 (en) | 2002-06-03 | 2008-07-31 | The Institute For Systems Biology | Methods for quantitative proteome analysis of glycoproteins |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| US7011949B2 (en) | 2002-09-30 | 2006-03-14 | Agilent Technologies, Inc. | Methods and compositions for producing labeled probe nucleic acids for use in array based comparative genomic hybridization applications |
| US7459273B2 (en) | 2002-10-04 | 2008-12-02 | Affymetrix, Inc. | Methods for genotyping selected polymorphism |
| EP1578994A2 (en) | 2002-11-11 | 2005-09-28 | Affymetrix, Inc. | Methods for identifying dna copy number changes |
| WO2004059293A2 (en) * | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| US20040146883A1 (en) | 2003-01-28 | 2004-07-29 | Affymetrix, Inc. | Methods for prenatal diagnosis |
| US7028629B2 (en) | 2003-02-03 | 2006-04-18 | Richard Walcome | Self-sealing port light assembly |
| EP1668360A4 (en) * | 2003-08-15 | 2007-08-08 | Univ Pittsburgh | MULTI FACTOR CANCER DETECTION TEST |
| US20060094064A1 (en) * | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
| AU2005241003B2 (en) | 2004-04-14 | 2011-05-19 | President And Fellows Of Harvard College | Nucleic-acid programmable protein arrays |
| EP1607898A3 (en) | 2004-05-18 | 2006-03-29 | Neal E. Solomon | A bioinformatics system for functional proteomics modelling |
| WO2005114221A2 (en) | 2004-05-21 | 2005-12-01 | The Institute For Systems Biology | Compositions and methods for quantification of serum glycoproteins |
| US20060024315A1 (en) * | 2004-06-02 | 2006-02-02 | Sidney Kimmel Cancer Center | Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| US9002652B1 (en) * | 2005-01-27 | 2015-04-07 | Institute For Systems Biology | Methods for identifying and using organ-specific proteins in blood |
| US7883858B2 (en) * | 2005-01-27 | 2011-02-08 | Institute For Systems Biology | Methods for identifying and monitoring drug side effects |
| CA2625403A1 (en) * | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| JP5244103B2 (ja) * | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
| CN102803955B (zh) * | 2009-05-21 | 2015-10-21 | 系统生物学研究所 | 肝损伤的新标志物 |
-
2007
- 2007-08-09 JP JP2009523868A patent/JP5244103B2/ja not_active Expired - Fee Related
- 2007-08-09 EP EP07836742A patent/EP2057465A4/en not_active Ceased
- 2007-08-09 US US12/376,951 patent/US8586006B2/en active Active
- 2007-08-09 AU AU2007284651A patent/AU2007284651B2/en not_active Ceased
- 2007-08-09 WO PCT/US2007/017868 patent/WO2008021290A2/en not_active Ceased
- 2007-08-09 EP EP12174646A patent/EP2520935A3/en not_active Ceased
- 2007-08-09 CA CA002660286A patent/CA2660286A1/en not_active Abandoned
-
2013
- 2013-11-05 US US14/072,651 patent/US20140106981A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010500568A (ja) | 2010-01-07 |
| WO2008021290A3 (en) | 2008-11-13 |
| US20120087862A1 (en) | 2012-04-12 |
| WO2008021290A2 (en) | 2008-02-21 |
| US8586006B2 (en) | 2013-11-19 |
| US20140106981A1 (en) | 2014-04-17 |
| WO2008021290A9 (en) | 2009-04-16 |
| AU2007284651B2 (en) | 2014-03-20 |
| EP2057465A2 (en) | 2009-05-13 |
| EP2520935A3 (en) | 2013-02-13 |
| EP2520935A2 (en) | 2012-11-07 |
| WO2008021290A8 (en) | 2008-04-17 |
| EP2057465A4 (en) | 2010-04-21 |
| JP5244103B2 (ja) | 2013-07-24 |
| AU2007284651A1 (en) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8586006B2 (en) | Organ-specific proteins and methods of their use | |
| JP2010500568A5 (enExample) | ||
| US20070099251A1 (en) | Tissue-and serum-derived glycoproteins and methods of their use | |
| CN105755112B (zh) | 结肠直肠癌的诊断 | |
| US8969009B2 (en) | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual | |
| US20090047689A1 (en) | Autoantigen biomarkers for early diagnosis of lung adenocarcinoma | |
| JP6786499B2 (ja) | 膵癌のバイオマーカー | |
| JP2018153184A (ja) | 広汎性発達障害の診断および治療のための組成物および方法 | |
| WO2008064336A2 (en) | Autoimmune disease biomarkers | |
| KR20120041175A (ko) | 미량 존재하는 인간 혈장 단백질 바이오마커의 신규 패널을 이용한 간성 섬유증의 임상적 진단 | |
| US20100210824A1 (en) | Method of Identifying Drugs, Targeting Moieties or Diagnostics | |
| US9410965B2 (en) | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual | |
| CN1864068B (zh) | 用小表位抗体降低样品复杂度的方法 | |
| KR20130046457A (ko) | 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트 | |
| US9347948B2 (en) | Phenyl glyoxal probes | |
| KR102131860B1 (ko) | 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물 | |
| EP2297580B1 (en) | Antibody against Ephrin Type-A receptor 7 for treatment of bladder cancer | |
| EP3157543B1 (en) | Compositions and methods for the diagnosis of systemic autoimmune disease | |
| US20140274758A1 (en) | Antibody profiling, methods and apparatus for identifying an individual or source of a biological material | |
| CN120913729A (zh) | 一种狼疮性肾炎的预测系统、电子设备及存储介质 | |
| KR20250015147A (ko) | 자폐증 장애 진단용 조성물 및 키트 | |
| CN116413430A (zh) | 一种用于肝癌早期预测的自身抗体/抗原组合及检测试剂盒 | |
| CA2917465A1 (en) | Miox antibody and assay | |
| KR20200077779A (ko) | 퇴행성 뇌질환 발병 위험성 예측용 조성물 및 이를 이용한 퇴행성 뇌질환의 발병 위험성 예측 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20200831 |